Adverum Biotechnologies Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
138
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$107M
- Investors
-
6
Adverum Biotechnologies General Information
Description
Developer of gene therapies designed to treat debilitating ocular diseases and prevent vision loss. The company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein to deliver long-term, durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
Contact Information
Website
www.adverum.com(Operating Subsidiary)
Corporate Office
- 100 Cardinal Way
- Redwood City, CA 94063
- United States
Corporate Office
- 100 Cardinal Way
- Redwood City, CA 94063
- United States
Adverum Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 09-Dec-2025 | $107M | Completed | Generating Revenue | ||
| 11. PIPE | 12-Aug-2025 | Completed | Generating Revenue | |||
| 10. PIPE | 08-Feb-2024 | Completed | Generating Revenue | |||
| 9. Secondary Transaction - Private | 01-Sep-2019 | Completed | Generating Revenue | |||
| 8. Secondary Transaction - Open Market | 01-Jun-2019 | Completed | Clinical Trials - Phase 3 | |||
| 7. PIPE | 01-Jan-2019 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Open Market | 01-Apr-2018 | Completed | Profitable | |||
| 5. 2PO | 08-Feb-2018 | Completed | Profitable | |||
| 4. Secondary Transaction - Open Market | 01-Jan-2017 | $163M | Completed | Profitable | ||
| 3. IPO | 31-Jul-2014 | $102M | $163M | Completed | Clinical Trials - Phase 3 |
Adverum Biotechnologies Comparisons
Industry
Financing
Details
Adverum Biotechnologies Competitors (75)
One of Adverum Biotechnologies’s 75 competitors is 4D Molecular Therapeutics, a Formerly VC-backed company based in Emeryville, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics | Formerly VC-backed | Emeryville, CA | ||||
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | ||||
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA |
Adverum Biotechnologies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Adverum Biotechnologies Patents
Adverum Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026019885-A1 | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept | Pending | 16-Jul-2024 | ||
| WO-2026006785-A2 | Melanopsin variants for vision restoration | Pending | 28-Jun-2024 | ||
| WO-2026006785-A3 | Melanopsin variants for vision restoration | Pending | 28-Jun-2024 | ||
| AU-2024364565-A1 | Anti-aav2.7m8 antibodies and methods of use thereof | Pending | 19-Oct-2023 | ||
| EP-4795082-A1 | Anti-aav2.7m8 antibodies and methods of use thereof | Pending | 19-Oct-2023 | G01N33/56983 |
Adverum Biotechnologies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Adverum Biotechnologies Former Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Adage Capital Management | Hedge Fund | Minority | ||
| Almi Invest | Venture Capital | Minority | ||
| Asset Management Ventures | Venture Capital | Minority | ||
| Cowen Healthcare Investments | Venture Capital | Minority | ||
| Deerfield Capital | Lender/Debt Provider | Minority |
Adverum Biotechnologies Acquisitions (1)
Adverum Biotechnologies’s most recent deal was a Merger/Acquisition with Annapurna Therapeutics for . The deal was made on 11-May-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Annapurna Therapeutics | 11-May-2016 | Merger/Acquisition | Drug Discovery |
Adverum Biotechnologies ESG
Risk Overview
Risk Rating
Updated March, 31, 2026
30.22 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Biotechnology
Subindustry
of 434
Rank
Percentile
Adverum Biotechnologies FAQs
-
When was Adverum Biotechnologies founded?
Adverum Biotechnologies was founded in 2006.
-
Where is Adverum Biotechnologies headquartered?
Adverum Biotechnologies is headquartered in Redwood City, CA.
-
What is the size of Adverum Biotechnologies?
Adverum Biotechnologies has 138 total employees.
-
What industry is Adverum Biotechnologies in?
Adverum Biotechnologies’s primary industry is Biotechnology.
-
Is Adverum Biotechnologies a private or public company?
Adverum Biotechnologies is a Private company.
-
What is the current valuation of Adverum Biotechnologies?
The current valuation of Adverum Biotechnologies is .
-
What is Adverum Biotechnologies’s current revenue?
The current revenue for Adverum Biotechnologies is .
-
How much funding has Adverum Biotechnologies raised over time?
Adverum Biotechnologies has raised $360M.
-
Who are Adverum Biotechnologies’s investors?
Adage Capital Management, Almi Invest, Asset Management Ventures, Cowen Healthcare Investments, and Deerfield Capital are 5 of 17 investors who have invested in Adverum Biotechnologies.
-
Who are Adverum Biotechnologies’s competitors?
4D Molecular Therapeutics, Caribou Biosciences, Voyager Therapeutics, Regenxbio, and Genetix Biotherapeutics are some of the 75 competitors of Adverum Biotechnologies.
-
When was Adverum Biotechnologies acquired?
Adverum Biotechnologies was acquired on 09-Dec-2025.
-
Who acquired Adverum Biotechnologies?
Adverum Biotechnologies was acquired by Lilly USA.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
